View Post

Alpha-TEA helps with breast cancer

In Clinical Trials by Barbara Jacoby

By: Christina Burkhart From: abc12.com One in eight women will be diagnosed with breast cancer at some point in her lifetime. One in four of those breast cancer diagnosis will be HER-2-positive. It’s an aggressive form of breast cancer and is more likely to recur than HER2-negative breast cancer. Now a new trial is underway to stop this cancer in …

View Post

Enobosarm Shows Clinical Benefit in AR+, ER+ Metastatic Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Gina Mauro From: onclive.com Enobosarm demonstrated clinical benefit at varying dose levels in patients with androgen receptor (AR)–positive, estrogen receptor (ER)–positive metastatic breast cancer, according to phase 2 findings of the G200802 study that were presented during the virtual 2020 San Antonio Breast Cancer Symposium.1,2 At the 9-mg and 18-mg doses of enobosarm, the 6-month clinical benefit rate (CBR) …

View Post

Trial results extend add to uses for Exact Sciences test

In Clinical Trials by Barbara Jacoby

By: Joel Berg From: medcitynews.com The genomic test, known as Oncotype DX, can help predict whether women with certain forms of breast cancer will benefit from chemotherapy — and those who won’t. The latest trial results extend the test’s reach. A clinical trial shows that a genomic test from diagnostics company Exact Sciences can help more women with early-stage breast …

View Post

ELAINE-2 Trial Could Establish the Actionability of ESR1 in HR+/HER2- Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Caroline Seymour From: onclive.com The ongoing ELAINE-2 trial (NCT04432454), which is evaluating the combination of lasofoxifene and abemaciclib (Verzenio) in patients with ESR1-mutant, estrogen receptor (ER)–positive, HER2-negative metastatic breast cancer, is building on findings from the ELAINE study, which demonstrated that the oral selective estrogen receptor modulator (SERM) has significant preclinical antitumor activity in ESR1-mutant models, said Matthew P. …

View Post

Dr. Kalinsky on Initial Results of the RxPONDER Trial in HR+/HER2- Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Kevin Kalinsky, MD, MS From: onclive.com Kevin Kalinsky, MD, MS, director of the Glenn Family Breast Center and Breast Medical Oncology at Winship Cancer Institute, and acting associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine, discusses the initial results of the phase 3 RxPONDER trial in patients with hormone receptor (HR)–positive, …

View Post

Postoperative Radiotherapy Can Be Omitted Without Impacting Metastatic Risk in Low-Grade Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Tony Berberabe From: onclive.com Whole breast irradiation (WBI), following breast-conserving surgery and adjuvant endocrine therapy, can be omitted from the treatment journey of low-risk, older patients with pT1-2 tumors (≥3 cm) who are on local control at 10 years, according to data from the PRIME 2 trial (ISRCTN9588932) presented during the 2020 San Antonio Breast Cancer Symposium.1 Investigators made …

View Post

FDA Approves Margetuximab-cmkb Plus Chemo in Pretreated Metastatic HER2+ Breast Cancer

In In The News by Barbara Jacoby

By: Kristi Rosa From: onclive.com The FDA has approved margetuximab-cmkb (Margenza) in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have previously received 2 or more anti-HER2 regimens, at least one of which for metastatic disease.1 The regulatory decision was based on findings from the phase 3 SOPHIA trial (NCT02492711), in which the …

View Post

Gilead Advances Oncology Portfolio With New Data From Phase 3 ASCENT Trial of Trodelvy® in Metastatic Triple Negative Breast Cancer

In Clinical Trials by Barbara Jacoby

From: .businesswire.com Gilead Sciences, Inc. (Nasdaq: GILD) is presenting new data from the Phase 3 ASCENT trial of Trodelvy® (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer (mTNBC) at the 2020 San Antonio Breast Cancer Symposium being held virtually December 8-11, 2020. The new data and analyses from the ASCENT trial continue to demonstrate the high clinical activity of Trodelvy in …

View Post

Updated Outcome and Treatment Benefit Data from MINDACT Study Reinforce Real-World Value of MammaPrint® for Clinical Low Risk Breast Cancer Patients

In Clinical Trials by Barbara Jacoby

From: businesswire.com Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that additional data from its groundbreaking MINDACT study will be highlighted in an oral presentation by Laura van ’t Veer, Ph.D., Co-founder and Chief Research Officer, at the 2020 San Antonio Breast Cancer Symposium (SABCS 2020). These data highlight the ability of MammaPrint®, Agendia’s 70-gene …